Core Insights - Ascletis Pharma Inc. has successfully completed the Phase III clinical trial for denifanstat (ASC40), demonstrating significant efficacy in treating moderate-to-severe acne vulgaris compared to placebo [1][4] - The company plans to submit a New Drug Application (NDA) to the China National Medical Products Administration (NMPA) following a pre-NDA consultation [2][3] Group 1: Clinical Trial Results - Denifanstat (ASC40) met all primary, key secondary, and secondary efficacy endpoints in the Phase III trial, showing significant improvement in acne vulgaris [1][4] - The safety profile of denifanstat (ASC40) was favorable, with all treatment-emergent adverse events being mild or moderate, and no serious adverse events reported [4] Group 2: Regulatory and Development Plans - Ascletis has completed the pre-NDA consultation with NMPA, which began in June 2025 and concluded in October 2025, and plans to submit the NDA soon [2][3] - The results of the Phase III study were presented at the European Academy of Dermatology and Venereology Congress in September 2025 [5] Group 3: Company Overview - Ascletis Pharma Inc. is a biotechnology company focused on developing therapeutics for metabolic diseases, utilizing advanced drug discovery technologies [6] - The company is listed on the Hong Kong Stock Exchange under the ticker 1672.HK [6]

Core Insights - Ascletis Pharma Inc. has selected ASC35, a once-monthly GLP-1R/GIPR dual peptide agonist, as a clinical development candidate for obesity treatment, with an IND submission expected in Q2 2026 [2][3][4] Group 1: Drug Efficacy and Characteristics - ASC35 has an average observed half-life of approximately 14 days in non-human primate studies, which is 6-fold longer than tirzepatide, supporting its once-monthly subcutaneous dosing in humans [1][4] - In head-to-head studies, ASC35 demonstrated approximately 71% greater relative body weight reduction compared to tirzepatide in diet-induced obese mice, with ASC35 reducing body weight by 33.6% versus 19.6% for tirzepatide [1][5][7] - ASC35 is approximately 4-fold more potent than tirzepatide for both GLP-1R and GIPR in vitro, indicating its potential as a best-in-class treatment for obesity [1][4][7] Group 2: Development and Technology - ASC35 was developed using Ascletis' proprietary Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies, which allow for optimized drug design and manufacturing scalability [4][10] - The pharmacokinetic relationship established in non-human primates suggests that ASC35 may have a predicted half-life of 30 days or longer in humans, enhancing its therapeutic profile [4][7] - Ascletis plans to explore combination studies of ASC35 with other therapeutic candidates, including ASC36 and ASC47, to address multiple metabolic diseases [9] Group 3: Strategic Vision - The selection of ASC35 reflects Ascletis' commitment to innovation in the treatment of obesity and metabolic diseases, complementing its existing portfolio of small molecule candidates [8] - The company aims to provide a more versatile and patient-friendly titration schedule with ASC35's once-monthly dosing [8]

Core Insights - Denifanstat (ASC40) has met all primary, key secondary, and secondary efficacy endpoints in treating moderate-to-severe acne compared to placebo [1][6][11] - The drug demonstrated a favorable safety and tolerability profile, with treatment-emergent adverse events (TEAEs) comparable to placebo [1][9] Efficacy Results - The Phase III clinical trial involved 480 patients, randomized into treatment and placebo groups, showing significant improvements in multiple efficacy endpoints after 4 weeks and 12 weeks of treatment [4][6] - Primary endpoints included a treatment success rate of 33.17% for denifanstat compared to 14.58% for placebo, with a p-value of <0.0001 [5][6] - Percent reductions from baseline to week 12 in total lesion count (TLC) and inflammatory lesion count (ILC) were 57.38% and 63.45% for denifanstat, respectively, both statistically significant [6][7] Safety Profile - The incidence of TEAEs was 58.6% for denifanstat and 56.3% for placebo, with most events being mild or moderate [9] - Notable TEAEs included 6.3% dry skin and 5.9% xerophthalmia in the denifanstat group, with no serious adverse events reported [9] Regulatory Progress - Ongoing pre-New Drug Application (NDA) consultation with the China National Medical Products Administration (NMPA) has yielded encouraging feedback, with plans to submit an NDA for denifanstat after consultation completion [2][11] Company Background - Ascletis Pharma Inc. is focused on developing and commercializing innovative therapeutics for metabolic diseases, utilizing advanced drug discovery platforms [13]

Core Insights - Ascletis Pharma Inc. presented promising results for its oral small molecule GLP-1 receptor agonist ASC30, demonstrating significant body weight reduction in participants with obesity during a 28-day multiple ascending dose study [3][4][9] Group 1: Study Results - ASC30 achieved a 6.5% placebo-adjusted mean body weight reduction from baseline in MAD cohort 2 after 28 days of treatment [4] - In MAD cohort 1, ASC30 showed a 4.5% placebo-adjusted mean body weight reduction from baseline after the same treatment duration [4] - The study indicated no signs of a plateau effect at Day 29, suggesting continued efficacy [4] Group 2: Safety and Tolerability - ASC30 was found to be safe and well tolerated, with only mild to moderate gastrointestinal adverse events reported [2][6] - No serious adverse events were recorded, and there were no Grade 3 or higher adverse events observed [7] - The titration strategy from 2 mg to 5 mg in MAD cohort 1 resulted in zero incidence of vomiting, indicating an appropriate escalation pace [6] Group 3: Pharmacokinetics - Higher doses of ASC30 (20 mg and 40 mg) demonstrated a superior pharmacokinetic profile, with a positive correlation between the area under the curve (AUC) and body weight reduction [5] - The pharmacokinetic data showed that the maximum concentration (Cmax) for MAD cohort 2 was 397 ng/mL, compared to 272 ng/mL for MAD cohort 1 [5] Group 4: Future Outlook - The company anticipates reporting topline results from the 13-week Phase IIa study of ASC30 in the fourth quarter of this year [9] - ASC30 is positioned as a differentiated treatment option for obesity, with both oral and subcutaneous administration routes [10][11]

Core Insights - Ascletis Pharma Inc. is set to present data from its Phase Ib clinical study of the oral GLP-1 receptor agonist ASC30 at the 61st EASD Annual Meeting in Vienna, Austria [1][2] - The company is on track to report topline data from a Phase IIa clinical study of ASC30 in participants with obesity or overweight by the fourth quarter of 2025 [1] Group 1: Clinical Study and Presentation - The 28-day multiple ascending dose study of ASC30 demonstrated superior weight loss in participants with obesity [2] - The short oral discussion will take place on September 16, 2025, from 12:00 to 13:00 CEST, with presentation number 827 [2] Group 2: Product Information - ASC30 is a new chemical entity (NCE) with unique properties allowing for both oral tablet and subcutaneous injection administration, protected by U.S. and global patents until 2044 [3] Group 3: Company Overview - Ascletis Pharma Inc. focuses on developing and commercializing therapeutics for metabolic diseases, utilizing its proprietary AI-assisted drug discovery platform [5] - The company is listed on the Hong Kong Stock Exchange under the ticker 1672.HK [5]

Core Insights - Ascletis Pharma Inc. announced promising preclinical efficacy results for ASC47, a first-in-class muscle-preserving weight loss drug candidate, in combination with ASC31, a dual-targeting peptide agonist for GLP-1R and GIPR [2][6] Group 1: Drug Candidates - ASC47 is an adipose-targeted, once-monthly subcutaneously injected thyroid hormone receptor beta (THRβ) selective small molecule agonist, developed in-house at Ascletis, which shows high drug concentrations in adipose tissue [4] - ASC31 is a novel peptide agonist targeting both GLP-1R and GIPR, demonstrating a favorable pharmacokinetic profile and promising efficacy in diet-induced obese (DIO) mice [3][5] Group 2: Efficacy Results - In a DIO mouse model, the combination of a low dose of ASC47 (9 mg/kg, SQ) with ASC31 (3 nmol/kg, SQ) resulted in a 44.8% reduction in body weight after 14 days, compared to a 38.1% reduction with ASC47 combined with tirzepatide [1][5] - The combination of ASC47 with ASC31 was found to be 17.6% more effective than the combination with tirzepatide, with statistical significance (p=0.02) [5] Group 3: Company Overview - Ascletis Pharma Inc. is focused on developing and commercializing potential best-in-class and first-in-class therapeutics for metabolic diseases, utilizing proprietary platforms for drug discovery [7]

Core Insights - Ascletis Pharma Inc. announced promising efficacy results from a study combining ASC47, a muscle-preserving weight loss drug candidate, with tirzepatide in diet-induced obese (DIO) mice [3][9] Group 1: Efficacy Results - The combination of ASC47 low dose with tirzepatide resulted in an 87% greater reduction in body weight compared to tirzepatide monotherapy, with average total body weight reductions of 38.1% versus 20.4% respectively [1][5] - ASC47 low dose combined with tirzepatide demonstrated a statistically significant increase in efficacy compared to ASC47 low dose combined with semaglutide, achieving 87% weight loss versus 55% [1][5] Group 2: Body Composition Restoration - The combination therapy restored the body composition of obese mice to levels similar to healthy non-obese mice, with total muscle mass percentages of 60.4% for the combination group compared to 62.0% for healthy controls [2][8] - Tirzepatide monotherapy did not restore body composition to healthy levels, indicating the potential superiority of the ASC47 and tirzepatide combination [8] Group 3: Drug Properties - ASC47 is a first-in-class, adipose-targeted, once-monthly subcutaneously injected thyroid hormone receptor beta (THRβ) selective small molecule agonist, developed in-house by Ascletis [4] - The drug's unique properties allow for high drug concentrations in adipose tissue, which may contribute to its efficacy in weight loss [4]

Core Insights - Ascletis Pharma Inc. has completed enrollment for its 13-week Phase IIa study of ASC30, a small molecule oral GLP-1 receptor agonist aimed at treating obesity, with 125 participants enrolled in just over one month [2][3]. Group 1: Study Details - The Phase IIa study is randomized, double-blind, placebo-controlled, and multi-center, focusing on participants with obesity (BMI ≥ 30 kg/m²) or overweight (BMI ≥ 27 kg/m² but < 30 kg/m²) who have at least one weight-related comorbidity [3][4]. - Two oral formulations of ASC30 are being evaluated: formulation 1 (ASC30 tablets) and formulation 2 (ASC30 tablets A1), with a primary endpoint of mean percentage body weight change from baseline at Week 13 [3][4]. - The study protocol starts with a low dose of 1 mg for both formulations, with weekly titrations to maintenance doses of 20 mg and 40 mg for formulation 1, and 20 mg, 40 mg, and 60 mg for formulation 2 [3]. Group 2: Product Information - ASC30 is a first and only investigational small molecule GLP-1R biased agonist, designed for both once-daily oral and once-monthly subcutaneous injection dosing options for obesity treatment [4][5]. - The compound has U.S. and global patent protection until 2044, ensuring its exclusivity in the market [5]. Group 3: Company Overview - Ascletis Pharma Inc. is a fully integrated biotechnology company focused on developing and commercializing therapeutics for metabolic diseases, utilizing proprietary platforms for drug discovery [6]. - The company is listed on the Hong Kong Stock Exchange under the ticker 1672.HK [6].

Core Insights - Ascletis Pharma Inc. has initiated a 12-week Phase IIa study in the U.S. for its once-monthly subcutaneous (SQ) depot formulation of the small molecule GLP-1 receptor agonist ASC30, targeting participants with obesity or overweight and at least one weight-related comorbidity [3][6] - The ASC30 formulation has demonstrated a 36-day half-life in a Phase Ib study, supporting its monthly administration [4][5] - Topline data from the Phase IIa study is expected in the first quarter of 2026 [2][6] Company Overview - Ascletis Pharma Inc. is a biotechnology company focused on developing and commercializing therapeutics for metabolic diseases, utilizing its proprietary Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD) Platform and Ultra-Long-Acting Platform (ULAP) [9][10] - ASC30 is a unique investigational GLP-1R biased small molecule agonist that can be administered both orally and subcutaneously, with patent protection until 2044 [8][10] Study Details - The Phase IIa study is randomized, double-blind, placebo-controlled, and multi-center, involving approximately 65 participants with obesity (BMI ≥ 30 kg/m²) or overweight (BMI ≥ 27 kg/m² but < 30 kg/m²) [6] - The study consists of three cohorts with different doses to evaluate safety, tolerability, and efficacy [6] Technical Insights - The ultra-long-acting SQ depot formulation of ASC30 has a peak-to-trough ratio of less than 2:1, which is critical for achieving acceptable tolerability for SQ dosing of incretin drugs [2][5] - ASC30 is the only once-a-month incretin in clinical development with a half-life greater than the intended dosing interval, which is essential for optimal tolerability [5]

Core Insights - Ascletis Pharma Inc. is conducting a randomized, double-blind, placebo-controlled study (ASC47-103) to evaluate the safety, tolerability, and preliminary efficacy of ASC47 in combination with semaglutide for obesity treatment [2][5] - The study has successfully enrolled 28 participants in less than two months, indicating strong interest in new obesity treatment options [3][8] - Topline data from the study is expected to be released in the fourth quarter of 2025 [4][8] Company Overview - Ascletis Pharma Inc. is a biotechnology company focused on developing and commercializing therapeutics for metabolic diseases, utilizing proprietary platforms for drug discovery [6] - The company is listed on the Hong Kong Stock Exchange under the ticker 1672.HK [6] Study Details - The ASC47-103 study includes three cohorts receiving single doses of ASC47 (10 mg, 30 mg, and 60 mg) or placebo, along with four doses of semaglutide (0.5 mg, once weekly) [5] - ASC47 is characterized as an ultra-long-acting subcutaneously administered thyroid hormone receptor beta selective small molecule agonist, with a half-life of up to 40 days [3][5] - In preclinical studies, ASC47 demonstrated superior fat mass reduction compared to semaglutide and tirzepatide in diet-induced obese mouse models [3]